First Evidence of the Protective Effects of 2-Pentadecyl-2-Oxazoline (PEA-OXA) in In Vitro Models of Acute Lung Injury
Laboratory studyHumansWith PEA-OXA (2-pentadecyl-2-oxazoline, a PEA analogue, tested alongside ultramicronised PEA)
This study tested palmitoylethanolamide together with PEA-OXA (2-pentadecyl-2-oxazoline, a PEA analogue, tested alongside ultramicronised PEA). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Human lung epithelial A549 cells activated by poly-(I:C) or TGF-beta
- Dose used in the study
- PEA-OXA or ultramicronised palmitoylethanolamide added to cell culture; concentrations not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- IL-6 release by ELISA; epithelial-mesenchymal transition by immunofluorescence; endogenous anandamide, 2-AG and PEA levels
What the authors reported
This in vitro study found:
- Both PEA-OXA and PEA reduced poly-(I:C)-induced IL-6 release and reversed TGF-beta-induced epithelial-mesenchymal transition.
- PEA raised anandamide and 2-AG levels, while PEA-OXA raised only endogenous PEA.
- PEA-OXA was described as superior to PEA in protective effect.
Limits of this study
A human cell-line study; it cannot show effect in people. Three authors are employees of Epitech Group SpA, and two hold patents on adelmidrol or PEA.
Source
PubMed 36671418 · doi:10.3390/biom13010033
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.